Acute phenylalanine/tyrosine depletion (APTD) has been proposed as a new method to decrease catecholamine neurotransmission safely, rapidly, and transiently. Validation studies in animals are encouraging, but direct evidence in human brain is lacking. In the present study, we tested the hypothesis that APTD would reduce stimulated dopamine (DA) release, as assessed by positron emission tomography (PET) and changes in [
INTRODUCTION
The acute phenylalanine/tyrosine depletion (APTD) method was recently developed as a new tool to investigate the effects of catecholamine neurotransmission in humans (Moja et al, 1996; Sheehan et al, 1996; Leyton et al, 2000b) . Initial studies suggest that APTD decreases subjective effects of amphetamine (McTavish et al, 1999b; Rot et al, 2003) , amphetamine-induced changes in impulse control (Rot et al, 2003) , alcohol self-administration in social drinkers (Leyton et al, 2000a) , withdrawal-related craving in nicotine-dependent smokers (Casey et al, 2002) , and mood both in healthy subjects (Leyton et al, 2000b; Harmer et al, 2001 ) and manic patients ).
An assumption in these studies is that APTD is inducing functionally significant decreases in brain catecholamine synthesis. Animal studies support this possibility. APTD decreases post-mortem tissue concentrations of the dopamine (DA) metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (Biggio et al, 1976) , amphetamine-induced DA release (McTavish et al, 1999a) , and cerebrospinal fluid (CSF) concentrations of HVA and the norepinephrine (NE) metabolite, 3-methoxy-4-hydroxyphenethyleneglycol (Palmour et al, 1998) . In humans, though, the evidence remains circumstantial: APTD is reported to decrease blood pressure (Moja et al, 1996) and increase circulating levels of prolactin ), but direct evidence of decreased catecholamine transmission in brain is lacking.
In the present study, we sought to assess whether APTD would reduce stimulated DA release in human striatum, as measured by positron emission tomography (PET) and [ 11 C]raclopride. Healthy subjects were administered a nutritionally balanced (BAL) amino-acid (AA) mixture containing the catecholamine precursors, phenylalanine and tyrosine, and, on a separate day, the phenylalanine/ tyrosine-deficient mixture. Ingestion of the latter mixture induces protein synthesis, leading to a transient reduction in the availability of phenylalanine and tyrosine for entry into the brain. Since the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase, is normally incompletely saturated (Carlsson and Lindqvist, 1978) , reduced availability of the AA precursors decreases DA and NE synthesis. On both test days, subjects received a low oral dose of d-amphetamine (0.3 mg/kg, p.o.). We recently reported that this dose of d-amphetamine decreases [ 11 C]raclopride binding potential (BP), and does so preferentially in the ventral striatum . We predicted that APTD would attenuate the ability of damphetamine to elicit DA release, as reflected by higher 
METHODS

Subjects
Eight healthy men (age, 23.1 7 3.6 years; weight, 72.1 7 10.9 kg) were recruited from advertisements placed in local newspapers and on campus. All were healthy nonsmokers, as determined by a physical exam, standard laboratory tests, and an interview using the Structured Clinical Interview for DSM-IV (First et al, 1995) . None had a first-degree relative history of axis I psychiatric disorders as assessed by Research Diagnostic Criteria for Family Histories (Andreasen et al, 1977) . On each day of the study, all tested negative on a urine drug screen sensitive to cocaine, opiates, phencyclidine, barbiturates, D
9
-tetrahydrocannabinol, benzodiazepines, and amphetamines (Triaget Panel for Drugs of Abuse, Biosite Diagnostics r , San Diego, CA, USA). The study was carried out in accordance with the Declaration of Helsinki and was approved by the Montreal Neurological Institute's Research Ethics Board.
Procedure
The day before each AA mixture test session, subjects ate a low protein diet provided by the investigators, and fasted from midnight. On the test day, subjects arrived at 0830 and had blood samples drawn to measure plasma AA concentrations. They then ingested one of the AA mixtures given in counter-balanced order. The APTD mixture's composition, preparation, and administration is based on our 100 gm nutritionally balanced mixture with phenylalanine and tyrosine withheld (Young et al, 1985; Leyton et al, 2000b) . Following ingestion of the mixture, participants remained awake in a room with videos, television, and reading material available to them. On both test days, an oral dose of d-amphetamine (Dexedrine, 0.3 mg/kg) was administered approximately 1.5 h before tracer injection (mean 7 SD, 1.4 7 0.5 h) and 3.5 h after administration of the AA mixture (3.6 7 0.5 h).
Subjects underwent two scans on separate days between 1400 and 1700 on a Siemens ECAT HR+ PET scanner (maximum resolution 4.1 Â 4.1 Â 4.5 mm 3 , full-width halfmaximum in center of field of view in air) with lead septa removed. At 1 h before tracer injection, a catheter was inserted into the subject's antecubital vein. Immediately before tracer injection, transmission scans were performed using 68 Ga for attenuation correction. Approximately, 10 mCi of [ 11 C]raclopride was injected as an intravenous (i.v.) bolus and data were acquired for 60 min in time frames of progressively longer duration.
High-resolution (1 mm) T1-weighted magnetic resonance (MR) images were obtained for all subjects (3D fast-field echo scans with 160 slices, 1 mm isotropic resolution, TR ¼ 18 ms, TE ¼ 10 ms, flip angle ¼ 301). These volumes were corrected for image intensity nonuniformity , and linearly and nonlinearly transformed into standardized stereotaxic space (Talairach and Tournoux, 1988) using automated feature matching to the MNI305 template (Collins et al, 1994b; Collins and Evans, 1997) . Each individual's MRI was then coregistered to their summed radioactivity PET images (Evans et al, 1992) . Inspection of the time activity curves suggested that one subject moved during one scan. Movement correction was made by applying an algorithm that corrects for betweenframe misalignment due to head movement. This coregistration method realigns each PET frame to a ligand-specific, MRI-derived, four-dimensional template, which represents radiotracer spatial distribution at each time point (Sechet et al, 2002; Reilhac et al, 2003) .
PET images were reconstructed with a filtered backprojection using a 6 mm full-width half-maximum Hanning filter. Parametric images were generated by calculating [ 11 C]raclopride BP (BP ¼ B Avail /K D ; B Avail ¼ density of available receptors) at each voxel, using a simplified reference tissue compartmental model with cerebellar activity as the reference (Lammertsma and Hume, 1996; Gunn et al, 1997 ). T-maps were then constructed, representing t-tests of change in [
11 C]raclopride BP between the two conditions; the voxel-by-voxel comparisons assessed the same voxels for every subject (Aston et al, 2000) . Clusters of statistically significant change were identified by thresholding the t-map at a value of tX4.2, which corresponds to po0.05 corrected for multiple comparisons and a search volume of the entire striatum (Worsley et al, 1996) .
BP values for each subject were extracted from the volume delineated by t-values greater than or equal to 4.2, as well as from five anatomical regions of interest (ROI). Identifying the ROI entailed three steps. First, each tissue type (gray matter, white matter, and CSF) was automatically classified (Collins et al, 1998) . Second, the striatum was delineated from a probabilistic brain atlas (Collins et al, 1994a) . Third, the study's ROI were drawn within the striatum's boundaries, based on the functional organization of limbic, associative, and sensory motor subcompartments as proposed by Laruelle, Haber, and co-workers (Haber and McFarland, 1999; Mawlawi et al, 2001; Martinez et al, 2003) ( Figure 1 ): ventral striatum (limbic striatum), precommissural dorsal caudate (posterior caudate/associative striatum), precommissural dorsal putamen (posterior putamen/associative striatum), postcommissural caudate (anterior caudate/associative striatum), and postcommissural putamen (anterior putamen/sensory motor putamen). The ROI were drawn on each subject's MRI to match their individual neuroanatomy, and the same regions were used for both the first and second scans. Corrections for partial volume effects were not made. For the analyses, left and right hemispheres were combined. In all, 10 consecutive 1 mm slices drawn in the cerebellum served as the reference region.
Plasma AA and Amphetamine Levels
Blood samples were drawn at morning baseline before AA mixture ingestion and 5 and 6 h later. Phenylalanine and tyrosine were measured using precolumn derivatization with o-phthalaldehyde and gradient reverse-phase HPLC with aminoadipic acid as an internal standard and fluorometric detection. Plasma concentrations of amphetamine were analyzed with electron-capture gas chromatography after extraction and derivatization of amphetamine with pentafluorobenzenesulfonyl chloride (Asghar et al, 2002) . Morning plasma samples were missing from three subjects, afternoon samples from one. 
RESULTS
APTD lowered plasma concentrations of phenylalanine and tyrosine, as reflected by significant AA mixture Â time interactions (tyrosine: F(1,4) ¼ 36.94, po0.004; phenylalanine: F(1,4) ¼ 36.83, po0.004). Compared to morning baseline, APTD decreased phenylalanine and tyrosine levels by 77.8 7 10.2 and 73.0 7 8.3%, respectively (mean 7 SD, po0.05). The BAL mixture, which contained phenylalanine and tyrosine, increased plasma levels of these AA by 71.9 7 53.0 and 135.2 7 56.5% (pp0.01) ( Table 1) . Amphetamine bioavailability did not differ on the two test days (BAL: 13.1 7 6.2; APTD: 13.2 7 6.4 ng/ml; p40.95).
Receptor parametric mapping indicated that on the two test sessions there were statistically significant differences in [ 11 C]raclopride BP in the ventral striatum (peak, t ¼ 6.31; x ¼ À25, y ¼ À8, and z ¼ 0) (Figure 2) . A t-test comparing [ 11 C]raclopride BP values extracted from this t-map defined region confirmed the significant difference; BP values were 11.8 7 11.9% higher on the APTD than BAL test day (t ¼ 2.90, df ¼ 7, po0.03) ( Table 2 ). In the five ROI, planned comparisons suggested an effect of AA mixture specific to the ventral striatum (pp0.02) and posterior putamen (pp0.01), although the AA mixture Â ROI interaction was not significant (F(4,28) ¼ 1.98, pp0.12) ( Table 2) .
The magnitude of decrease in [ 11 C]raclopride BP correlated with plasma tyrosine levels following APTD (Figure 3 ). Significant correlations were seen in the t-map Figure 1 Depicted is a schematic representation of ROI, as defined by Mawlawi et al (2001) . On the left, the ROI are delineated by ANIMAL-INSECT segmentation (Collins and Evans, 1997) 8 mm rostral to the anterior commissure. On the right, hand drawn ROI are superimposed over an averaged MRI, coronal plane (x ¼ 8). VS: limbic ventral striatum, composed of the nucleus accumbens and both the ventral putamen and ventral caudate rostral to the anterior commissure; DP: sensory motor dorsal putamen; DC: associative dorsal caudate. 
DISCUSSION
The present study suggests that acute depletion of the catecholamine precursors, phenylalanine and tyrosine, attenuates the ability of d-amphetamine to elicit DA release in the ventral striatum. To our knowledge, these results provide the first evidence that APTD decreases stimulated DA release in human brain. The effect of APTD on d-amphetamine-induced changes in striatal [ 11 C]raclopride BP was restricted to limbic and associative subcompartments, as defined by Laruelle, Haber, and co-workers (Haber and McFarland, 1999; Mawlawi et al, 2001; Martinez et al, 2003) . This agrees with previous observations that d-amphetamine preferentially decreases [ 11 C]raclopride BP in these regions (Drevets et al, 2001 ; Leyton et al, 2002; Martinez et al, 2003) . Animal studies suggest that this reflects regional differences in drug-induced increases in synaptic DA levels (Di Chiara and Imperato, 1988) rather than an artifact of the PET method. Mechanisms proposed to mediate this preferential effect include regional variability in DA release, and in the density and activity of DA transporters and DA cell innervation (Haber and McFarland, 1999; Wu et al, 2001) .
A reanalysis of previously published data indicates that, in the region identified here, damphetamine (0.3 mg/kg, p.o.), compared to placebo, reduces BP values by 12.7%. Although one might conclude that APTD nearly completely prevented this effect (11.8/ 12.7 ¼ 92.9%), differences in the two studies caution against a direct comparison. For example, different individuals participated in the two protocols, there is substantial interindividual variability in both [
11 C]raclopride BP and amphetamine-induced changes in [
11 C]raclopride BP, and ingesting a BAL mixture prior to receiving d-amphetamine might be different from receiving the psychostimulant without the AA mixture.
The ability of APTD to decrease plasma levels of tyrosine correlated with the attenuation of d-amphetamine-induced DA release. Linear regression analyses suggest that the association between plasma tyrosine levels and the ability of d-amphetamine to release DA has a steep slope (eg y ¼ À0.34x+19.27: equation for plasma tyrosine vs percent change in [ 11 C]raclopride BP in the t-map). The steepness of slope may be accounted for by the fact that tyrosine hydroxylase is typically 75% saturated with tyrosine (Carlsson and Lindqvist, 1978) . The Michaelis-Menten curve suggests that modest decreases in tyrosine availability would have limited effects on the enzyme's hydroxylation rate; below a certain level, though, hydroxylation would be expected to plummet. The present study suggests that APTD can achieve the necessary level of depletion.
The effect of APTD on [ 11 C]raclopride BP is similar to the effect of the tyrosine hydroxylase inhibitor, a-methyl-paratyrosine (aMPT). In a study conducted in non-human primates, d-amphetamine (0.3 mg/kg, i.v.) decreased [
123 I]IBZM binding by 25%; this effect was reduced to À12% when d-amphetamine administration was preceded by aMPT (Laruelle et al, 1997b) .
The APTD method has a number of advantages as a tool to decrease catecholamine neurotransmission. For example, aMPT requires repeated administration and a minimum of 3 days in-hospital observation (Verhoeff et al, 2001) ; its administration can induce crystalluria (Brogden et al, 1981) and acute dystonic reactions (McCann et al, 1990) . In comparison, APTD can induce measurable effects within 3 h Figure 3 Correlation between plasma levels of tyrosine, following phenylalanine/tyrosine depletion, and the ability of d-amphetamine to elicit DA release. Note that plasma data were missing for one subject. In this individual, catecholamine depletion increased [ 11 C]raclopride binding by 11.3% in the t-map. Casey et al, 2002) , is not associated with severe side effects, and does not require overnight observation. A potential disadvantage of APTD is that, like aMPT, it appears to decrease both DA and NE synthesis (Palmour et al, 1998) . However, recent behavioral data suggest that it may be possible to distinguish between dopaminergic and noradrenergic effects based on which are prevented by the immediate DA precursor, L-3,4-dihydroxyphenylalanine (Casey et al, 2002; Rot et al, 2003) . Studies in rodents suggest that a variant of the APTD mixture containing seven instead of 14 AAs might decrease DA synthesis selectively (McTavish et al, 1999b) , but this remains a subject of ongoing investigation.
The results of the present study should be interpreted in light of the following considerations. First, a two-by-two factorial design would have permitted us to assess more directly the size of APTD's effect on d-amphetamineinduced DA release. Restrictions on permitted radiation exposure precluded conducting four scans in the same individuals. However, the primary objective of the current study was to assess whether stimulated DA release is less when subjects are pretreated with APTD as compared to BAL. The results indicate that this occurs. Second, the sample size is modest (n ¼ 8); however, it is within the norms for assessing effects of pharmacological challenges within subjects and the effect exceeds po0.05, Bonferroni corrected. The correlations were obtained with only seven subjects, but the association is consistent with the presumed mechanism of action for APTD. Third, the drug that was administered to stimulate DA release, d-amphetamine, was given p.o. rather than i.v. Oral drug administration is associated with lower and more variable bioavailability (Angrist et al, 1987; Ylitalo, 1991) . Nonetheless, plasma levels of amphetamine did not differ on the two test sessions, and we have previously shown that the dose used here induces significant decreases in [ 11 C]raclopride BP in ventral striatum (Fujita et al, 2000) . However, these changes are thought to reflect aMPT-induced decreases in synaptic DA levels. Autoradiography studies in rats indicate that aMPT does not alter striatal DA D2 receptor K D or B max (Laruelle et al, 1997a) . Fifth, catecholamines can affect cerebral blood flow, and the present results could reflect altered delivery or washout of the tracer. However, simulation studies indicate that even large changes in blood flow have negligible effects on receptor ligand binding, as measured by the method used here (Aston et al, 2000) . Sixth, the present study did not evaluate whether APTD would decrease extracellular DA levels in the absence of a challenge. Some evidence suggests that the effects of APTD are more pronounced under challenge conditions. In microdialysis studies, APTD diminishes d-amphetamine-induced increases in DA release without affecting extracellular DA levels at predrug resting baseline (McTavish et al, 1999b) . Larger effects under challenge conditions might reflect the fact that tyrosine hydroxylase activity is regulated, in part, by intraneuronal catecholamine stores (Ames et al, 1978) . Lowered stores, due to catecholamine release, would be expected to increase tyrosine hydroxylase activity, making DA synthesis more vulnerable to lowered tyrosine availability. Our previous studies suggest that behavioral effects of APTD might also be seen more consistently under challenge conditions (Leyton et al, 2000b; Rot et al, 2003) . Seventh, the PET [ 11 C]raclopride method is unable to detect extrastriatal changes in DA release, and the effect of APTD in these other regions is unknown. Finally, both the behavioral and neurochemical effects of tryptophan-deficient AA mixtures might be larger in women than in men ; whether this is true for APTD remains to be assessed.
In conclusion, the present study indicates that APTD decreases stimulated DA release in human striatum. The observation validates the method in human brain, and suggests that APTD is a suitable new tool for neuropsychopharmacology research in humans.
